Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

348255

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services: West Midlands
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his Department has to review mental health provision in the West Midlands; and if he will make a statement.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	1026
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>This is a matter for the National Health Service locally. NHS England advises that Coventry and Rugby Clinical Commissioning Group (CCG), is working along with South Warwickshire CCG, Warwickshire North CCG, Coventry City Council and Warwickshire County Council, on a joint review of the specifications for children and adolescent mental health services.</p><p> </p><p> </p><p> </p><p>In the current financial year Coventry and Rugby CCG will put an additional £1.2 million towards the mental health services it commissions.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt grouped question UIN 1027 question first answered 08/06/2015 14:24:51 answering member 1201 label Biography information for Alistair Burt
tabling member	308 label Biography information for Mr Jim Cunningham

348256

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services: West Midlands
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his Department has to make additional resources available for mental health services in the West Midlands over the next five years; and if he will make a statement.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	1027
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>This is a matter for the National Health Service locally. NHS England advises that Coventry and Rugby Clinical Commissioning Group (CCG), is working along with South Warwickshire CCG, Warwickshire North CCG, Coventry City Council and Warwickshire County Council, on a joint review of the specifications for children and adolescent mental health services.</p><p> </p><p> </p><p> </p><p>In the current financial year Coventry and Rugby CCG will put an additional £1.2 million towards the mental health services it commissions.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt grouped question UIN 1026 question first answered 08/06/2015 14:24:51 answering member 1201 label Biography information for Alistair Burt
tabling member	308 label Biography information for Mr Jim Cunningham

348257

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Antimicrobials: Drug Resistance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his Department has to make additional funding available to tackle drug-resistant infections over the next five years.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	1028
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>The health and care system across the United Kingdom is taking action against the growing threat of infections that are resistant to the antimicrobial drugs used to treat them.</p><p> </p><p> </p><p> </p><p>In December 2014, we published the UK Five Year AMR Strategy detailed implementation plan. The plan set out those activities that needed to be undertaken to deliver the strategy in each of seven key areas for action. Activity in the plan is led by the Department of Health, Public Health England, Department for Environment, Food and Rural Affairs and NHS England and is incorporated within existing business plans for those organisations.</p><p> </p><p> </p><p> </p><p>The Government has no current plans to make additional funding available to tackle drug-resistant infections. Any proposals for funding would be subject to the outcome of the Spending Review later this year.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/06/2015 10:54:59 answering member 3918 label Biography information for Jane Ellison
tabling member	308 label Biography information for Mr Jim Cunningham

348258

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Infectious Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the number of drug-resistant infections (a) in the West Midlands and (b) nationally in the next five years.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	1029
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Public Health England (PHE) has published no estimates for the number of drug-resistant infections in the West Midlands or nationally over the next five years. The science of drug resistant infections is incompletely understood and is rapidly changing and evolving. Multi-drug resistant infections are unpredictable in their occurrence and can rapidly change. For these reasons producing estimates of the likely burden in future years is unlikely to be meaningful or robust.</p><p> </p><p> </p><p> </p><p>Antimicrobial resistance is a priority for PHE who are working to improve surveillance and knowledge in this area. Specific antimicrobial resistant infections have been measured by PHE and openly published in weekly Health Protection Reports.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/06/2015 10:58:32 answering member 3918 label Biography information for Jane Ellison
tabling member	308 label Biography information for Mr Jim Cunningham

348377

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Tobacco: Packaging
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what preparations his Department is making for the commencement of the Standardised Packaging of Tobacco Products Regulations 2015 on 20 May 2016.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	1058
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Guidance will be made available to local authority trading standards officers, or in the case of Northern Ireland, environmental health officers. It will be developed with the relevant bodies responsible and made publically available before the Standardised Packaging of Tobacco Products Regulations 2015 come into force.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/06/2015 15:28:25 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

348390

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Motor Vehicles: Smoking
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what preparations his Department is making for the commencement of the Smoke-free (Private Vehicles) Regulations 2015 on 1 October 2015.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	1077
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>There will be a communications campaign to raise awareness of the Smoke-free (Private Vehicles) Regulations 2015 in advance of them coming into force on 1 October. Guidance and training materials are currently being developed and will be available for the police and local authority enforcement officers. Information will be available for local authorities so that they can work locally to help build compliance and raise awareness.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/06/2015 14:30:03 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

348391

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cervical Cancer: Health Education
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the contribution of the Parliamentary Under-Secretary of State for Health of 1 May 2014, Official Report, column 1052, on cervical cancer screening, whether Ministers in his Department hosted a special day in Parliament on the take-up of cervical cancer screening and HPV vaccinations.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	1100
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>As I said in the debate on 1 May 2014, Official Report, column 1052, if hon. and Rt. hon. Members indicated that they would want to initiate a Parliamentary event on cervical screening and the Human Papilloma Virus (HPV) vaccination, I would be happy to support it. Although, to date, I have received no specific representations from any hon. or Rt. hon. Members, I remain happy to support such an event.</p><p> </p><p> </p><p> </p><p>In April 2012 the UK National Screening Committee (UKNSC) gave its support for a pilot to assess the value of using HPV testing as primary screening (HPV TaPS) for cervical disease, rather than the currently used cytology test. The pilot is establishing the feasibility of using HPV testing as the primary screen for cervical disease in order to achieve better outcomes for women, while minimising over-treatment and anxiety, and whether it is practical to roll out nationally. The UK NSC will open a public consultation shortly on whether HPV TaPS for cervical disease should replace the currently used cytology test.</p><p> </p><p> </p><p> </p><p>Public Health England (PHE) continues to work with NHS England via the Public Health Section 7A agreement to develop a system of performance improvement through the use of performance floors, and strengthened governance for screening. The aims of the performance floors are:</p><p> </p><p><br> - Improving performance and equity of service over time by reducing the range of variation at a local level.</p><p> </p><p>- Enabling easy identification of poor performance and the setting of objectives and plans for local action, to reduce variation and improve performance.</p><p> </p><p> </p><p> </p><p>PHE will look at research provided by the STRATEGIC study (Strategies to increase cervical screening uptake at first invitation) to identify methods to help increase uptake among women. The STRATEGIC study will be publishing findings in May 2016, more details of this can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nets.nihr.ac.uk/projects/hta/0916401" target="_blank">http://www.nets.nihr.ac.uk/projects/hta/0916401</a></p><p> </p><p> </p><p> </p><p>The Responsibility Deal Health at Work Network has worked with employers to develop the Staff Health Checks pledge, which encourages eligible employees to participate in NHS Health, and other NHS screening programmes. 160 employers have signed up to this pledge.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 1101 question first answered 08/06/2015 15:54:52 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

348392

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cervical Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the contribution of the Parliamentary Under-Secretary of State for Health of 1 May 2014, Official Report, column 1052, on cervical cancer screening, what steps his Department has taken to modernise the NHS cervical cancer screening programme; what progress has been made by Public Health England on addressing low coverage of cervical cancer screening in certain areas and working on local action plans to improve such coverage; and what work his Department has carried out with employers to encourage them to make it clear to young women that they will facilitate them taking time off for cervical cancer screening.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	1101
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>As I said in the debate on 1 May 2014, Official Report, column 1052, if hon. and Rt. hon. Members indicated that they would want to initiate a Parliamentary event on cervical screening and the Human Papilloma Virus (HPV) vaccination, I would be happy to support it. Although, to date, I have received no specific representations from any hon. or Rt. hon. Members, I remain happy to support such an event.</p><p> </p><p> </p><p> </p><p>In April 2012 the UK National Screening Committee (UKNSC) gave its support for a pilot to assess the value of using HPV testing as primary screening (HPV TaPS) for cervical disease, rather than the currently used cytology test. The pilot is establishing the feasibility of using HPV testing as the primary screen for cervical disease in order to achieve better outcomes for women, while minimising over-treatment and anxiety, and whether it is practical to roll out nationally. The UK NSC will open a public consultation shortly on whether HPV TaPS for cervical disease should replace the currently used cytology test.</p><p> </p><p> </p><p> </p><p>Public Health England (PHE) continues to work with NHS England via the Public Health Section 7A agreement to develop a system of performance improvement through the use of performance floors, and strengthened governance for screening. The aims of the performance floors are:</p><p> </p><p><br> - Improving performance and equity of service over time by reducing the range of variation at a local level.</p><p> </p><p>- Enabling easy identification of poor performance and the setting of objectives and plans for local action, to reduce variation and improve performance.</p><p> </p><p> </p><p> </p><p>PHE will look at research provided by the STRATEGIC study (Strategies to increase cervical screening uptake at first invitation) to identify methods to help increase uptake among women. The STRATEGIC study will be publishing findings in May 2016, more details of this can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nets.nihr.ac.uk/projects/hta/0916401" target="_blank">http://www.nets.nihr.ac.uk/projects/hta/0916401</a></p><p> </p><p> </p><p> </p><p>The Responsibility Deal Health at Work Network has worked with employers to develop the Staff Health Checks pledge, which encourages eligible employees to participate in NHS Health, and other NHS screening programmes. 160 employers have signed up to this pledge.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 1100 question first answered 08/06/2015 15:54:53 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

348398

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate his Department has made of the number of people with hidradenitis suppurativa in the UK; how much his Department has spent on research into hidradenitis suppurativa in the last four years; and what guidance his Department gives on support to be given through the NHS for people with hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	963
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 962 964 965 question first answered 08/06/2015 10:54:00 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

348399

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the effectiveness of the care pathways for patients with hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	964
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 962 963 965 question first answered 08/06/2015 10:54:00 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper